ZA201509262B - Tuberculosis compositions and methods of using the same - Google Patents

Tuberculosis compositions and methods of using the same

Info

Publication number
ZA201509262B
ZA201509262B ZA2015/09262A ZA201509262A ZA201509262B ZA 201509262 B ZA201509262 B ZA 201509262B ZA 2015/09262 A ZA2015/09262 A ZA 2015/09262A ZA 201509262 A ZA201509262 A ZA 201509262A ZA 201509262 B ZA201509262 B ZA 201509262B
Authority
ZA
South Africa
Prior art keywords
methods
same
tuberculosis compositions
tuberculosis
compositions
Prior art date
Application number
ZA2015/09262A
Other languages
English (en)
Inventor
Walker Barry
Stone Michele
G Evans Thomas
Cadieux Nathalie
Anantha Ravi
Original Assignee
Aeras Global Tb Vaccine Found A Corporation Organised And Existing Under The Laws Of The District Of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeras Global Tb Vaccine Found A Corporation Organised And Existing Under The Laws Of The District Of filed Critical Aeras Global Tb Vaccine Found A Corporation Organised And Existing Under The Laws Of The District Of
Publication of ZA201509262B publication Critical patent/ZA201509262B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2015/09262A 2013-06-25 2015-12-18 Tuberculosis compositions and methods of using the same ZA201509262B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361838872P 2013-06-25 2013-06-25
PCT/US2014/043889 WO2014210018A1 (en) 2013-06-25 2014-06-24 Tuberculosis compositions and methods of using the same

Publications (1)

Publication Number Publication Date
ZA201509262B true ZA201509262B (en) 2017-11-29

Family

ID=52111114

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/09262A ZA201509262B (en) 2013-06-25 2015-12-18 Tuberculosis compositions and methods of using the same

Country Status (7)

Country Link
US (4) US10266574B2 (enExample)
EP (2) EP3013364B1 (enExample)
JP (2) JP6554095B2 (enExample)
CN (1) CN105431166B (enExample)
ES (1) ES2925950T3 (enExample)
WO (1) WO2014210018A1 (enExample)
ZA (1) ZA201509262B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201500171YA (en) * 2012-07-10 2015-02-27 Transgene Sa Mycobacterial antigen vaccine
EP3013364B1 (en) * 2013-06-25 2022-08-03 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
EP3092000A1 (en) * 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
WO2016120489A2 (en) * 2015-02-01 2016-08-04 Theravectys Lentiviral vectors for expression of mycobacterium tuberculosis antigens
US10428122B2 (en) * 2016-06-16 2019-10-01 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
AU2017280065B2 (en) * 2016-06-22 2021-07-01 International Aids Vaccine Initiative, Inc. Recombinant cytomegalovirus vectors as vaccines for tuberculosis
EP3555630B1 (en) 2016-12-14 2023-05-31 Becton, Dickinson and Company Methods and compositions for obtaining a tuberculosis assessment in a subject
CN108239660B (zh) * 2016-12-26 2021-08-10 上海生物制品研究所有限责任公司 一种重组结核病疫苗，其制备方法及应用
US11642405B2 (en) * 2017-06-19 2023-05-09 Washington University Nanoemulsion and methods of use thereof
WO2019079155A1 (en) 2017-10-17 2019-04-25 International Aids Vaccine Initiative, Inc. CASSETTES OF ANTIGENS OF TUBERCULOSIS
KR102135334B1 (ko) * 2018-12-19 2020-07-17 대한민국 결핵 다가 항원을 발현하는 재조합 아데노 바이러스 및 이를 포함하는 결핵 예방용 조성물
CN116327906B (zh) * 2021-12-22 2026-03-20 中国人民解放军总医院第八医学中心 一种结核分枝杆菌串联dna疫苗w545及其制备方法与应用
CN117777259B (zh) * 2024-02-23 2024-06-07 上海科新生物技术股份有限公司 检测结核感染的抗原组合物、试剂盒及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
ES2249760T3 (es) 1993-01-26 2006-04-01 The Trustees Of The University Of Pennsylvania (A Corporation Of Pennsylvania) Composiciones y procedimientos de administracion de materias geneticas.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
DK1827504T3 (da) 2004-12-01 2011-08-29 Aeras Global Tb Vaccine Foundation Rekombinante BCG-stammer med forøget evne til at undslippe fra endosomet
US7968105B2 (en) 2005-06-23 2011-06-28 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
BRPI0620693A2 (pt) * 2005-12-15 2016-12-13 Aeras Global Tb Vaccine Found método para suscitar uma resposta imune tanto sistêmica como de mucosa a mycobacteria viva atenuada ou antígenos micobacterianos em um hospedeiro
WO2008124647A2 (en) * 2007-04-04 2008-10-16 Infectious Disease Research Institute Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
US8361482B2 (en) 2007-11-27 2013-01-29 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease
US7670609B2 (en) * 2007-11-27 2010-03-02 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease
CN101289496B (zh) 2008-05-30 2011-06-29 中国医学科学院医学生物学研究所 能激发机体抗结核杆菌的保护性免疫反应的抗原表位筛选方法及用途
WO2010129339A2 (en) 2009-04-28 2010-11-11 The Johns Hopkins University Compositions and methods for enhancing antigen-specific immune responses
GB0918154D0 (en) 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
US20120219582A1 (en) 2009-11-02 2012-08-30 Mie University Intranasal spray-type tuberculosis vaccine using paramyxovirus vector
LT2528621T (lt) 2010-01-27 2016-12-12 Glaxosmithkline Biologicals S.A. Modifikuoti tuberkuliozės antigenai
US20120003256A1 (en) 2010-03-01 2012-01-05 Huiling Han Tuberculosis antigens, immunogenic compositions, diagnostics and methods related to the same
GB201008512D0 (en) 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
SG11201500171YA (en) * 2012-07-10 2015-02-27 Transgene Sa Mycobacterial antigen vaccine
EP3013364B1 (en) 2013-06-25 2022-08-03 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
CN104474538A (zh) 2014-08-13 2015-04-01 华中科技大学 一种重组卡介苗

Also Published As

Publication number Publication date
ES2925950T3 (es) 2022-10-20
EP3013364A4 (en) 2017-05-31
CN105431166B (zh) 2020-09-18
US20240101612A1 (en) 2024-03-28
JP2019187441A (ja) 2019-10-31
EP3013364B1 (en) 2022-08-03
EP4176897A1 (en) 2023-05-10
CN105431166A (zh) 2016-03-23
US20140377300A1 (en) 2014-12-25
US20190322709A1 (en) 2019-10-24
JP2016529223A (ja) 2016-09-23
WO2014210018A1 (en) 2014-12-31
JP7269806B2 (ja) 2023-05-09
US10266574B2 (en) 2019-04-23
US11787842B2 (en) 2023-10-17
US11014969B2 (en) 2021-05-25
US20210371474A1 (en) 2021-12-02
EP3013364A1 (en) 2016-05-04
JP6554095B2 (ja) 2019-07-31

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
IL286759A (en) Therapeutic methods and preparations
GB2521022B (en) Compositions and methods
IL265876A (en) Preparations that include 15-ohepa and methods of using them
SG11201509136YA (en) Cenicriviroc compositions and methods of making and using the same
SMT201900635T1 (it) Composizioni e metodi di attivazione della segnalazione dipendente dallo "stimolatore di geni interferone"
GB201308072D0 (en) Compositions and methods
GB201317286D0 (en) Composition and Use
GB201321693D0 (en) Composition and uses thereof
EP3013364A4 (en) Tuberculosis compositions and methods of using the same
IL239840A0 (en) Polymyxins, preparations, methods of preparation and methods of use
GB201305813D0 (en) Compositions and methods
SG11201510150VA (en) Immunotherapy composition and use thereof
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
IL245034A0 (en) Pesticides and related methods
GB201322456D0 (en) Radiotracer compositions and methods
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same
GB201322617D0 (en) Methods and compositions
GB201312393D0 (en) Compositions and Methods
GB201319255D0 (en) Therapeutic compositions and methods
GB201322467D0 (en) Composition and use
GB201308242D0 (en) Compositions and uses thereof
GB201310349D0 (en) Composition and method of use thereof